These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28711090)

  • 1. The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis.
    Mittal L; Werth VP
    J Am Acad Dermatol; 2017 Aug; 77(2):374-377. PubMed ID: 28711090
    [No Abstract]   [Full Text] [Related]  

  • 2. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
    Mittal L; Zhang L; Feng R; Werth VP
    J Am Acad Dermatol; 2018 Jan; 78(1):100-106.e1. PubMed ID: 28989103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study.
    Ang GC; Werth VP
    Arch Dermatol; 2005 Jul; 141(7):855-9. PubMed ID: 16027300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse cutaneous drug reactions with antimalarials in cutaneous lupus and dermatomyositis: A retrospective cohort study.
    Gonzalez CD; Hansen C; Clarke JT
    J Am Acad Dermatol; 2019 Sep; 81(3):859-860. PubMed ID: 31085265
    [No Abstract]   [Full Text] [Related]  

  • 5. Practice Gaps. Optimizing antimalarial therapy for cutaneous lupus erythematosus: comment on "Response to antimalarial agents in cutaneous lupus erythematosus".
    Callen JP
    Arch Dermatol; 2011 Nov; 147(11):1267-8. PubMed ID: 22106112
    [No Abstract]   [Full Text] [Related]  

  • 6. Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus-An Ongoing Need for International Consensus and Collaborations.
    Concha JSS; Patsatsi A; Marshak-Rothstein A; Liu ML; Sinha AA; Lee LA; Merola JF; Jabbari A; Gudjonsson JE; Chasset F; Jarrett P; Chong B; Arkin L; Fernandez AP; Caproni M; Greenberg SA; Kim HJ; Pearson DR; Femia A; Vleugels RA; Fiorentino D; Fujimoto M; Wenzel J; Werth VP
    J Invest Dermatol; 2019 Feb; 139(2):270-276. PubMed ID: 30243657
    [No Abstract]   [Full Text] [Related]  

  • 7. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus.
    Pelle MT; Callen JP
    Arch Dermatol; 2002 Sep; 138(9):1231-3; discussion 1233. PubMed ID: 12224986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practice and Educational Gaps in Lupus, Dermatomyositis, and Morphea.
    Fett NM; Fiorentino D; Werth VP
    Dermatol Clin; 2016 Jul; 34(3):243-50. PubMed ID: 27363879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Quinacrine in the treatment of cutaneous lupus erythematosus: practical aspects and a case series].
    González-Sixto B; García-Doval I; Oliveira R; Posada C; García-Cruz MA; Cruces M
    Actas Dermosifiliogr; 2010; 101(1):54-8. PubMed ID: 20109393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candidate drug replacements for quinacrine in cutaneous lupus erythematosus.
    Yan D; Borucki R; Sontheimer RD; Werth VP
    Lupus Sci Med; 2020 Oct; 7(1):. PubMed ID: 33082164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.
    Chang AY; Piette EW; Foering KP; Tenhave TR; Okawa J; Werth VP
    Arch Dermatol; 2011 Nov; 147(11):1261-7. PubMed ID: 21768444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus.
    Feldmann R; Salomon D; Saurat JH
    Dermatology; 1994; 189(4):425-7. PubMed ID: 7873836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mepacrine in Recalcitrant Cutaneous Lupus Erythematosus: Old-fashioned or Still Useful?
    Benoit S; Goebeler M
    Acta Derm Venereol; 2015 May; 95(5):596-9. PubMed ID: 25474442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pigmented oral mucosa due to quinacrine.
    López-Jornet P; Pons-Fuster A
    N Y State Dent J; 2011 Nov; 77(6):49-51. PubMed ID: 22338819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of smoking in cutaneous lupus erythematosus.
    Piette EW; Foering KP; Chang AY; Okawa J; Ten Have TR; Feng R; Werth VP
    Arch Dermatol; 2012 Mar; 148(3):317-22. PubMed ID: 22105815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center.
    Femia AN; Eastham AB; Lam C; Merola JF; Qureshi AA; Vleugels RA
    J Am Acad Dermatol; 2013 Oct; 69(4):654-7. PubMed ID: 24034377
    [No Abstract]   [Full Text] [Related]  

  • 17. Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement.
    Hanjani NM; Nousari CH
    Arch Dermatol; 2002 Dec; 138(12):1616-8. PubMed ID: 12472362
    [No Abstract]   [Full Text] [Related]  

  • 18. Response of dermatomyositis to the antimalarial quinacrine: A retrospective cohort study.
    Ravishankar A; Yan D; Bax CE; Concha JS; Feng R; Werth VP
    J Am Acad Dermatol; 2021 Apr; 84(4):1157-1160. PubMed ID: 32712056
    [No Abstract]   [Full Text] [Related]  

  • 19. Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience.
    Kindle SA; Wetter DA; Davis MD; Pittelkow MR; Sciallis GF
    Int J Dermatol; 2016 Aug; 55(8):e431-9. PubMed ID: 26873674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.
    Chasset F; Arnaud L; Costedoat-Chalumeau N; Zahr N; Bessis D; Francès C
    J Am Acad Dermatol; 2016 Apr; 74(4):693-9.e3. PubMed ID: 26850655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.